Introduction
============

Liquid chromatography--mass spectrometry (LC--MS) techniques employed in drug metabolism studies of early drug discovery very often utilize the so called generic gradient elution, i.e. only structure group-optimized or even totally non-optimized eluent pH and gradient strength are used for all analytes (Lee and Kerns, [@B15]; Cheng et al., [@B4]; Hop et al., [@B8]; Kostiainen et al., [@B10]; Castro-Perez et al., [@B3]: Kamel and Prakash, [@B9]; Pedraglio et al., [@B16]). This provides high throughput and fast turn-around time, and is usually considered as the approach giving the highest amount of data with the lowest time consumption. The use of non-optimized test conditions however may lead to sacrificed data quality for many compounds, producing biased results, often in a form of false negatives in metabolite screening.

Despite their common use in industry, performance and data quality obtained with such methods are however rarely studied, at least in format of published data with a high number of compounds with diverse chemical nature. Also not much attention is paid to what kind of eluent conditions in case of LC--MS analysis would lead to highest general applicability, even though it is very well known that with LC--ESI--MS acidic compounds are usually negatively ionized (deprotonated) in basic conditions and basic compounds are on the contrary positively ionized (protonated) in acidic conditions (Kostiainen and Kauppila, [@B11]). The electrospray ionization process in LC--MS is however a very complex phenomenon having multiple affecting factors, such as volatility, viscosity, surface tension, conductivity, ion strength, and pH of the used solvents and additives in LC mobile phase, and depending on the properties of analyte compounds and mobile phase constituents, sometimes better ionization may occur in the conditions clearly against these rules (Kostiainen and Kauppila, [@B11]). In addition, the chromatographically co-eluting matrix components may suppress or enhance the ionization process (Mallet et al., [@B12]; Cappiello et al., [@B2]). Therefore, mobile phase constituents have very high and sometimes unpredictable effect to the ESI response of the analytes, and solvents and additives used must be carefully chosen and tested to obtain high-quality data from analyses.

Chromatographically valid data of gradient pH conditions considering the generic elution gradients with a very high number of compounds is described in the literature by Law ([@B14]), resulting in a conclusion that gradient elution at neutral pH conditions is highly successful for most compounds, as long as logD values of the analytes are \> --2. If the pH is increased above 8, the chromatographic performance for acidic compounds is weakened, whereas the pH below 4 decreases the performance with basic compounds. This study did not examine the effect of pH from the mass spectrometric point of view. Despite the chromatographic performance, most of the generic gradient conditions for drugs or drug-like compounds are at pH conditions 3--4 or even below, as in most cases with LC--MS utilizing electrospray ionization (ESI) the protonation (and thus detection sensitivity) is favored at this pH, especially with basic compounds.

Some papers focusing on development of generic gradients for LC--MS have been published, describing however the use of only minor groups of compounds (2--13 compounds), and thus not showing the real applicability of the methods for compounds of higher chemical diversity (Ayrton et al., [@B1]; Chu et al., [@B5]; Seto et al., [@B17]; Mensch et al., [@B13]). Ayrton et al. ([@B1]) described the development of generic HPLC--UV gradient elution conditions for 11 compounds, but tested the method only for two compounds with mass spectrometric detection. Seto et al. ([@B17]) in turn described a generic gradient LC--MS method with ion pairing reagents, considering the use of various mobile phase additives, but focusing on analysis of only four acidic compounds. Chu et al. ([@B5]) built up a generic LC--MS--MS method for *in vitro* blood--brain barrier test assay; showing its applicability with 28 new chemical entities (NCE). They however applied both positive and negative mode ionization polarities with both ESI and APCI ionization modes; and three different chromatographic columns for compounds with different retention behavior, so that the methods used in the end were really not so "generic". Also Mensch et al. ([@B13]) described a generic UPLC--MS--MS method for analysis of NCEs in drug discovery phase permeability studies, but only six model compounds were used in evaluating the performance of the method. The effect of eluent pH on chromatographic and mass spectrometric performance in generic gradient elution was most comprehensively studied by Delatour, who concluded that with their 11 basic drugs the basic pH provided clearly better chromatography in comparison to acidic conditions, without significant decrease in positive ion mode ESI--MS detection (Delatour and Leclercq, [@B7]).

Our actual goal was to develop LC--ESI--MS methods to be used in *in vitro* metabolism studies of 55 chemically diverse compounds in rat and human liver microsome and homogenate incubations, monitoring both substrate depletion and metabolite formation at the same time. The compounds were selected from the list of validation substances of European Centre for the Validation of Alternative Methods (ECVAM), and they have been used to study the comparison of metabolic properties in rat and human liver homogenate and microsomal incubations *in vitro*. The ECVAM list of validation compounds is not based on chemical classes (acids, bases, neutrals, amphoterics) but rather on the different toxicities of the compounds. For this reason the final set contained a relatively high number of chemically neutral compounds, so that this class of compounds was present in a clearly higher proportion than neutral compounds in drug discovery in general (Law, [@B14]). However, as the multiresidual techniques are nowadays of high importance in several analytical fields, such as metabolism, environmental and forensic sciences, or plant and human metabolomics, the search of compromise between optimal conditions for chromatographic separation, and detection is of great interest also in the application areas other than drug metabolism studies.

The methods for each compound were developed with one generic method as a starting point, and testing the effect of eluent pH on both chromatographic performance and mass spectrometric ionization efficiency (detection sensitivity). The data acquired during this stage was combined and analyzed here for assessing whether certain conditions would show the best general applicability in this type of studies, and thus evaluating the performance of the most typical gradient elution conditions for LC--ESI--MS used in drug discovery studies. It is worth stressing that our aim was not to develop one set of LC--MS conditions that would enable analysis of samples from all 55 test compounds; therefore the pH and the ion strengths of the LC effluents were not optimized more than by using six of the most typically used LC--MS aqueous mobile phases.

Materials and Methods
=====================

Chemicals
---------

All chemicals and solvents were HPLC grade and were purchased from VWR International Ltd (Espoo, Finland). LichroSolv acetonitrile was from Merck KGaA (Darmstadt, Germany), while formic acid, acetic acid, ammonium formate, ammonium acetate, and ammonia were from BDH Laboratories Ltd (Poole, England). Laboratory water was prepared with Direct-Q (Millipore S.A., Molsheim, France) water purification system and was UP grade (ultrapure, 18.2 MΩ).

Sample preparation
------------------

The test samples were prepared to provide similar injection conditions with real incubation samples. Thus, samples were prepared to 0.5 μM concentration in 50% acetonitrile in 150 mM phosphate buffer, so that this corresponds to 1 μM incubation (4% of the initial substrate concentration of 25 μM to be used in the following metabolism studies) where enzymatic reactions are quenched with an equal volume of acetonitrile.

Liquid chromatography mass spectrometry
---------------------------------------

A Waters Alliance 2695 high performance liquid chromatographic system (Waters Corp., Milford, MA, USA) with an autosampler, a column oven, and a vacuum degasser was used with Waters XBridge Shield RP18 column and Phenomenex Luna C18 (2 × 4 mm) precolumn. In some cases also Waters XBridge C18 or Phenomenex Luna-C18 columns were used if poor peak shape was observed with the first tested column. All columns used had 2.0--2.1 × 50 mm dimensions and 3--3.5 μm particle sizes. The column selection was based on stationary phases able to cover wide pH range (XBridge C18 pH 1--12, XBridgeShieldRP pH 2--11, Luna 1.5--10) and authors' good experiences about the columns over several years in various chromatographic conditions. Temperature of column oven was 30°C and injection volumes used were 10 μl. The data was acquired with a Micromass LCT time of flight (TOF) mass spectrometer (Micromass Ltd., Manchester, England) equipped with a LockSpray electrospray ionization source, used both in positive and negative ion polarity. Cone voltages between 16 and 28 V were used (roughly optimized for each compound). Capillary voltages of 3.5 and 2.8 kV were used at positive and negative ion mode, respectively. Nitrogen was used as a nebulizer and drying gas with flow rates of 100 and 800 l/h, respectively. The source and desolvation temperatures used were 150 and 350°C, respectively. Leucine encephalin (\[M+H\]^+^ *m*/*z* 556.2771) and raffinose (\[M--H\]^--^ *m*/*z* 503.1612) were used as lock mass compounds in accurate mass measurement with positive and negative ion modes, respectively, and were delivered into LockSpray probe with syringe pump to obtain about 160 counts/s. The mass spectrometer and HPLC system were operated under MassLynx 4.0 software.

Chromatographic conditions and method development
-------------------------------------------------

In method development phase the study compounds were divided to batches of 3--10 compounds, based on their chemical structures or acid/base properties, and LC--MS conditions for each compound were briefly optimized by acquiring test data for all compounds in a single batch at the same time. As a first run conditions a gradient elution with 2%--2%--60%--90%--90% acetonitrile in 0--1--3--5--6 min was applied for each compound (in batches of 3--10 compounds), followed by column equilibration. After this, few runs for optimizing gradient strength (slope of the organic phase proportion) were acquired, followed by runs with various aqueous phase pH conditions and different MS ionization polarities. In all cases, gradient elution was used (no isocratic runs). Acetonitrile was chosen as organic eluent phase over methanol, as it usually provides better chromatographic peak shapes. The eluent flow rate used was 0.4 ml/min. The aqueous eluent phases used were 0.1% formic acid (FA, pH 2.8), 0.1% acetic acid (AA, pH 3.2), 0.05% acetic acid +5 mM ammonium acetate (pH 4.4), 2 mM ammonium formate (NH~4~OF, pH 6.0), 2 mM ammonium acetate (NH~4~OAc, pH 6.7), and 10 mM ammonia (NH~4~OH, pH 9.8). After this the acquired data was used to extract the optimum LC--MS conditions for each single compound; and these methods were used later in *in vitro* metabolism studies (data to be reported elsewhere). For compounds with poor peak shape, also the effect of different columns (see above) were tested for improving chromatographic peak shapes.

Results and Discussion
======================

Suitability of generic gradient conditions for the test set compounds
---------------------------------------------------------------------

The suitability of the tested HPLC eluent conditions for each 55 test compounds are shown in Table [1](#T1){ref-type="table"}. Mass spectrometric ionization efficiencies were rated for each compound with symbols to mark detection sensitivity (a) high enough for monitoring formed metabolites "++", (b) good enough to monitor substrate depletion but not the formed metabolites "+", or (c) poor sensitivity being not enough even to monitor substrate depletion "−". The sensitivity limit for monitoring metabolites (metabolite profiling) was considered as signal-to-noise ratio \>10 from 1% concentration of the actual initial incubation concentration (25 μM), whereas the limit for monitoring substrate depletion was considered as a detected signal (S/N \> 3) from test sample having 4% concentration of the actual initial incubation concentration. When chromatographic problems were observed, in form of poor peak shape or inadequate retention behavior (to separate parent and metabolites) preventing the use of certain eluent conditions for metabolite profiling despite of good ionization, the abovementioned symbol was marked within parentheses "(++)". Poor peak shape was specified as asymmetric factor *A*/*B* \< 0.4 (tailing peak) or *A*/*B* \> 2 (fronting peak), where *A* = peak width before the peak top and *B* = peak width after the peak top (both measured from 5% peak height). As the chromatographic separation or peak shape are not so crucial in analysis of metabolic stability, this chromatographic criteria was not applied to "+" − symbols. The criterion for adequate retention was set so that normalized retention time (retention time minus dead time) should be at least ten times the peak width (measured from 5% peak height). In addition, the number of each symbol for each HPLC conditions in Table [1](#T1){ref-type="table"} is summarized to Table [2](#T2){ref-type="table"}. In addition, the best conditions for each compound were marked with a "\*" symbol.

###### 

**Performance obtained for the 55 test compounds in the tested LC--ESI--TOF--MS mobile phase conditions**.

  Compound                                               Class        Parent ion   0.1% FA    0.1% AA   2 mM NH~4~OF   5 mM NH~4~OAc +0.05% AA   2 mM NH~4~OAc   10 mM NH~4~OH                                                    
  ------------------------------------------------------ ------------ ------------ ---------- --------- -------------- ------------------------- --------------- --------------- ------- ------- ------- ------ ------- --------- -------
  Acetaminophen                                          Acid         152.0711     150.0555   −         −              +,\*                      −               (++)            −       \+      \+      −      −       \+        \+
  Chloramphenicol                                        Acid         323.0201     321.0045   −         ++             −                         ++              −               ++      −       ++      −      ++      −         ++,\*
  Cycloheximide                                          Acid         282.1705     280.1549   \+        \+             \+                        ++              ++              ++      \+      ++,\*   \+     ++      ++        ++
  Diphenylhydantoin                                      Acid         253.0977     251.0821   −         \+             −                         ++              −               ++      −       ++      −      ++,\*   −         ++
  Gibberellic acid                                       Acid         347.1494     345.1338   −         ++             −                         ++              −               ++,\*   −       ++      −      \+      −         (++)
  Ibuprofen                                              Acid         207.1385     205.1229   −         −              −                         ++              −               ++      −       ++,\*   −      −       −         ++
  Pentobarbital                                          Acid         227.1395     225.1239   −         \+             −                         ++              −               ++,\*   −       ++      −      ++      −         ++
  Phenobarbital                                          Acid         233.0926     231.0770   −         \+             −                         ++              −               ++,\*   −       ++      −      ++      −         −
  Propylparaben                                          Acid         181.0864     179.0708   −         \+             −                         ++•             −               ++      −       ++,\*   −      ++      −         ++
  Warfarin                                               Acid         309.1127     307.0971   ++        ++             ++                        ++              ++              ++      ++      ++,\*   ++     ++      ++        ++
  Aminoglutethimide                                      Amphoteric   233.1290     231.1134   ++        −              ++,\*                     −               (++)            −       ++      −       (++)   −       (++)      −
  Aminopterin                                            Amphoteric   441.1635     439.1479   (++)      (++)           ++,\*                     ++              (++)            −       ++      ++      −      −       −         −
  Nalidixic acid                                         Amphoteric   233.0926     231.0770   ++        −              ++,\*                     −               (++)            −       ++      \+      (++)   −       (++)      −
  Amitriptylinc hcl                                      Base         278.1908     276.1752   ++        −              ++,\*                     −               (++)            −       ++      −       (++)   −       (++)      −
  Amphetamine                                            Base         136.1126     134.0970   −         −              −                         −               (++)\*          −       \+      −       −      −       \+        −
  Antipyrine                                             Base         189.1028     187.0872   (++)      −              (++)                      −               ++\*            −       ++      −       (++)   −       ++        −
  Atropine sulfate                                       Base         290.1756     288.1600   ++        −              (++)                      −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Caffeine                                               Base         195.0882     193.0726   −         −              −                         −               (++)\*          −       (++)    −       −      −       (++)      −
  Carbamazcpine                                          Base         237.1028     235.0872   ++        −              ++                        −               ++,\*           −       ++      −       ++     −       ++        −
  Dextropropoxyphene                                     Base         340.2276     338.2120   ++        −              ++                        −               (++)            −       ++,\*   −       (++)   −       ++        −
  Diazepam                                               Base         285.0794     283.0638   ++        −              ++                        −               ++,\*           −       ++      −       ++     −       ++        −
  Diphenhydramine                                        Base         256.1701     254.1545   ++        −              ++                        −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Disopyramide                                           Base         340.2389     338.2233   ++        −              ++                        −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Haloperidol                                            Base         376.1479     374.1323   ++        \+             ++,\*                     −               (++)            −       ++      ++      (++)   −       (++)      (++)
  Isoniazid                                              Base         138.0667     136.0511   −         −              −                         −               +,\*            −       −       −       −      −       −         −
  Maprotiline                                            Base         278.1908     276.1752   ++        −              ++,\*                     −               (++)            −       ++      −       (++)   −       (++)      −
  Methadone                                              Base         310.2171     308.2014   −.−.      −              ++                        −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Methylphenidate                                        Base         234.1494     232.1338   ++        −              ++                        −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Nicotine                                               Base         163.1235     161.1079   \+        −              \+                        −               (++)            −       \+      −       −      −       ++,\*     −
  Orphenadrine                                           Base         270.1858     268.1701   ++        −              ++                        −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Physostigmine                                          Base         276.1712     274.1556   (++)      −              (++)                      −               ++,\*           −       ++      −       ++     −       ++        −
  Procainamide                                           Base         236.1763     234.1607   −         −              −                         −               (++)            −       (++)    −       −      −       (++),\*   −
  Propranolol                                            Base         260.1650     258.1494   ++        −              ++                        −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Quinidine sulfate                                      Base         325.1916     323.1760   (++)      −              ++                        −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Strychnine                                             Base         335.1759     333.1603   ++        −              (++)                      −               (++)            −       ++,\*   −       (++)   −       (++)      −
  Theophylline                                           Base         181.0725     179.0569   −         −              −                         −               (++),\*         (++)    −       −       −      \+      −         \+
  Thioridazine                                           Base         371.1615     369.1459   ++        −              ++,\*                     −               (++)            −       (++)    −       (++)   −       (++)      −
  Verapamil                                              Base         455.2910     453.2754   ++        −              ++                        −               (++)            −       ++,\*   −       (++)   −       ++        −
  Abamectin                                              Neutral      873.5000     871.4844   \+        \+             \+                        \+              ++              ++      ++      ++,\*   ++     ++      ++        ++
  Aflatoxin B1                                           Neutral      313.0712     311.0556   ++        −              ++                        \+              ++,\*           ++      ++      \+      ++     ++      ++        \+
  Busulfan                                               Neutral      247.0310     245.0154   −         −              −                         −               +,\*            −       \+      −       \+     −       \+        −
  Carbaryl                                               Neutral      202.0868     200.0712   \+        −              \+                        −               ++,\*           −       ++      −       −      −       ++        −
  Chlorpyrifos                                           Neutral      349.9341     347.9185   −         −              −                         −               ++,\*           −       \+      −       −      −       \+        −
  Colchicine                                             Neutral      400.1760     398.1604   ++        −              ++                        \+              ++,\*           ++      ++      ++      ++     ++      ++        ++
  Dibutyl phthalate                                      Neutral      279.1596     277.1440   ++        −              ++,\*                     −               ++              −       ++      −       \+     −       ++        −
  Diethyl phthalate                                      Neutral      223.0970     221.0814   \+        −              \+                        −               +,\*            −       \+      −       −      \-      \+        −
  Digoxin                                                Neutral      781.4374     779.4218   \+        ++             \+                        ++              ++              ++      ++      ++      \+     ++      ++        ++,\*
  Diuron                                                 Neutral      233.0248     231.0092   ++        \+             ++                        ++              ++              ++      ++      ++,\*   ++     ++      ++        ++
  Fenpropathrin                                          Neutral      350.1756     348.1600   −         −              −                         −               ++,\*           −       −       −       −      −       −         −
  Fenvalerate                                            Neutral      420.1366     418.1210   \+        −              −                         −               ++,\*           −       −       −       −      −       −         −
  Fipronil                                               Neutral      436.9465     434.9309   −         ++             −                         ++,\*           −               ++      −       ++      −      ++      −         ++
  Malathion                                              Neutral      331.0439     329.0283   \+        −              \+                        −               ++,\*           −       ++      −       ++     −       ++        −
  Metalaxyl                                              Neutral      280.1549     278.1393   ++        −              ++                        −               ++,\*           −       ++      −       ++     −       ++        −
  Parathion                                              Neutral      292.0408     290.0252   −         −              −                         −               +,\*            −       −       −       −      −       −         −
  Rotenone                                               Neutral      395.1494     393.1338   ++        −              ++                        \+              ++              ++      ++      ++      ++     ++      ++,\*     \+
  Total number of compounds with ++ in each conditions   29                        35                   27                                       41                              18              25                               

++*, detection sensitivity good enough for metabolite profiling; +, detection sensitivity good enough for monitoring substrate disappearance but not for metabolite profiling; −, poor detection sensitivity; (++), good ionization but poor chromatographic performance (inadequate retention or poor peak shape); \*, best conditions; FA, formic acid; AA, acetic acid; NH~4~OF, ammonium formate; NH~4~OAc, ammonium acetate; NH~4~OH, ammonia*.

###### 

**Number of different symbols in Table [1](#T1){ref-type="table"} in the tested LC--ESI--TOF--MS mobile phase conditions**.

         0.1% FA   0.1% AA   2 mM NH~4~OF   5 mM NH~4~OAc+0.05% AA   2 mM NH~4~OAc   10 mM NH~4~OH                            
  ------ --------- --------- -------------- ------------------------ --------------- --------------- ---- ---- ---- ---- ---- ----
  ++     25        5         25             13                       19              16              32   17   11   14   19   12
  \+     8         8         8              4                        4               0               7    3    4    2    5    4
  (++)   4         1         4              0                        24              1               3    0    18   0    17   2
  −      18        41        18             38                       8               38              13   35   22   39   14   37

As already mentioned above, the test compound set was not selected primarily for the analytical considerations discussed in the present study, but rather focused to obtain a suitable test set for metabolism studies. For this reason the number of neutral compounds is relatively high with respect to other classes, whereas only few amphoteric compounds are included. Even if the 55 compounds offer structurally quite a diverse selection of compounds, the number is still not very high, as some metabolomics studies may describe methods monitoring several hundreds of compounds at the same time. However, metabolomics studies do not provide similar approach for the assessment of analytical conditions as followed here.

Generally, and not surprisingly, the results showed clearly that none of the six eluent pH conditions was able to provide adequate analytical conditions to cover successful metabolite profiling, or even monitoring the substrate depletion, for all the 55 test compounds. However, suitable conditions for monitoring at least the substrate disappearance were found for all of the 55 test compounds. As expected, the positive ion mode electrospray ionization covered a higher number of test compounds in all conditions, even when working with ammonia in clearly basic conditions at pH 9.8. However, this latter result is somewhat biased by a high number of basic compounds in test group (bases 25/55, acids 10/55). The results are collected to Table [1](#T1){ref-type="table"}. It is obvious that negative ion mode was superior in ionization efficiency with acidic compounds in all tested pH conditions, whereas the basic compounds were self-evidently ionized better with positive ion mode. The neutral compounds were generally ionized with positive ion mode, and suitability of negative ion mode increased with increasing pH.

Of the six tested eluent conditions, the one with 0.05% acetic acid and 5 mM ammonium acetate (pH 4.4) showed the highest suitability for the test compounds, as 41 of the 55 compounds showed LC--MS performance filling the criteria set as adequate for metabolite profiling, either with positive or negative ion mode, when using this eluent. More specifically, 31 of the test compounds worked well in positive ion mode and 17 in negative ion mode (Table [2](#T2){ref-type="table"}). The actual strength of these conditions seemed to be a good chromatographic performance for most of the compounds, as only three compounds showed inadequate chromatographic retention behavior or poor peak shape. However, 13 of the test compounds showed completely inadequate performance even for monitoring substrate depletion in these conditions due to poor detection sensitivity. Also, even though the mobile phase with 0.05% acetic acid and 5 mM ammonium acetate showed the best general suitability for the test compounds, it was the best aqueous mobile phase only for 17 of the compounds. This again shows that even though this mobile phase is generally highly useful, it still leads to a less than-optimal performance for most of the compounds.

The second highest suitability was obtained with 0.1% acetic acid (pH 3.2) as an aqueous mobile phase, as for 35 out of 55 compounds the criteria set for monitoring both substrate depletion and the forming metabolites were fulfilled either with positive or negative ion mode. More specifically, 25 of the compounds filled the criteria in positive ion mode ionization, and 13 in negative ion mode ionization. The chromatographic performance was found unsuitable for seven compounds. The 0.1% acetic acid as an aqueous mobile phase provided the best performance for ten of the 55 compounds.

In terms of the number of compounds fulfilling the set criteria for metabolite profiling, either with positive or negative ion mode electrospray ionization, the suitability of 0.1% formic acid (pH 2.8), 2 mM ammonium formate (pH 6.0) and 10 mM ammonia (pH 9.8) were generally about equal, all leading to an adequate performance for 25--29 compounds. Clear differences between these three mobile phases were however apparent: 2 mM ammonium formate was the best aqueous mobile phase for 22 of the compounds, while ammonia was the most suitable only for five of the compounds, and formic acid was not the best for any of the 55 compounds. This latter issue is worth stressing, as though several mobile phase conditions gave performance that fulfilled the criteria set for metabolite profiling (marked "\*\*"), large, even over 10-fold, sensitivity differences were observed between them in some cases. The 2 mM ammonium acetate was suggested to have clearly the lowest general suitability for the analysis of the used test compounds, as the metabolite profiling criteria were fulfilled only with 18 of the 55 compounds. The relatively poor performance with ammonium acetate and formic acid as mobile phase additives is somewhat unexpected and worth noticing, as these both are commonly used in LC--ESI--MS.

With 2 mM ammonium formate, 2 mM ammonium acetate, and 10 mM ammonia as an aqueous mobile phase, it was clearly observed that most of the detected problems were introduced by inadequate chromatographic performance (poor peak shape), not by the mass spectrometric ionization properties. The Table [2](#T2){ref-type="table"} shows that when using 2 mM ammonium formate as an aqueous mobile phase, there were 24 compounds for which positive ion mode ESI ionization response high enough for metabolite profiling was observed, but at the same time their chromatographic properties were very poor and non-suitable for the intended study. When using 2 mM ammonium acetate and 10 mM ammonia as an aqueous eluent phase, the corresponding numbers of compounds with good ionization but poor chromatography were 18 and 17, respectively. In this context there was a striking difference between these three aqueous mobile phases and the mixture containing 0.05% acetic acid and 5 mM ammonium acetate (pH 4.4) providing clearly better chromatographic performance for a large set of compounds. This effect was most distinct for basic compounds, as peak shapes for acidic and neutral compounds were generally clearly better. An example of the pH/mobile phase additive effect for peak shapes is shown in Figure [1](#F1){ref-type="fig"}, where propranolol has very poor tailing peaks when ammonium formate, ammonium acetate and ammonia are used in aqueous mobile phase (traces C, E, and F), but on the contrary very good chromatographic performance when formic acid, acetic acid or mixture of ammonium acetate and acetic acid are used (traces A, B, and D). The ion strengths of the buffers were intentionally kept rather low to provide a good ESI--MS ionization efficiency, which may in some cases be the reason for the observed poor chromatographic peak shapes. Thus, from the chromatographical point of view higher buffer ion strength would improve the quality of the data for certain compounds, but this would also lead to clearly lower ionization response and thus poorer detection sensitivity.

![**Positive ion mode LC--ESI--TOF--MS ion chromatograms for propranolol at various mobile phase pH conditions**. **(A)** 0.1% formic acid (pH 2.8); **(B)** 0.1% acetic acid (pH 3.2); **(C)** 2 mM ammonium formate (pH 6.0); **(D)** 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); **(E)** 2 mM ammonium acetate (pH 6.7); **(F)** 10 mM ammonia (pH 9.8).](fphar-01-00010-g001){#F1}

The injection conditions may have their effect to the poor peak shapes in some cases. The acetonitrile content (50%) in injection solvent has clearly increased elution strength with respect to the initial gradient conditions (2%), causing some fronting in the peak shape if too high injection volumes are used. This phenomenon is clearly more pronounced with analytes that have low retention, which again in turn increases the importance of good chromatographic retention behavior. We however deliberately did not change the injection solvent, as in *in vitro* metabolism studies the samples usually contain high content of organic solvent used for quenching the enzymatic reactions in the incubations, and in high throughput analyses it is often a waste of time to evaporate the organic solvent or dilute the sample with aqueous solvent. Moreover, also in the high throughput *in vivo* plasma or serum analyses the samples are often prepared with protein precipitation with acetonitrile, using ratios 2:1--4:1 between solvent and sample, leading to even stronger injection solvents than used here.

The column chemistries (particle surface modification) have slight effect to the observed results. As stated above, our column selection was based on need for wide range pH tolerance for the columns, and good experiences with the used column chemistries in various demanding analyses. It may however be the case that some columns with narrower pH range (traditionally pH 2--7) might have produced better chromatographic behavior for certain compounds, but then again those could not have been used in all tested pH conditions. Also, the use of even higher pH (\>12) than the highest pH used here could have provided better chromatographic performance for strong bases, but this again would have led to poor applicability with most columns available.

Considering that the mass spectrometer used is from the beginning of the decade, and taking into account the dramatic increase in detection sensitivity with the recent TOF instruments, it is also clear that if such high study compound concentrations are used in metabolism studies as described in this paper, the new instruments are capable for detection sensitivity adequate for metabolite profiling even in slightly misoptimized analytical conditions. However, to obtain more meaningful results, especially regarding the parent compound disappearance (substrate depletion for the estimation of metabolic stability), the incubation concentrations should reflect more truthfully the concentrations observed in circulation *in vivo*, i.e. around 1 μM. With these kinds of parent compound levels even the modern instruments need again optimal conditions in order to provide high-quality data for metabolism studies.

Acids
-----

The test group contained 10 compounds classified as acids. Obviously, the negative ion mode ESI was clearly more sensitive for almost all of them in all tested pH conditions, only exceptions being observed with acetaminophen, cycloheximide, and warfarin. Observed sensitivity was adequate for metabolite profiling in negative ion mode for all other acidic compounds except acetaminophen when aqueous phase used was 0.1% acetic acid (pH 3.2), 2 mM ammonium formate (pH 6.0), or mixture of 0.05% acetic acid and 5 mM ammonium acetate (pH 4.4). Naturally, the acidic pH provided also good chromatographic peak shape and retention behavior for these compounds. When eluent pH was \<3 or \>7, the ionization efficiency started to decrease for some of the acids. Also as expected, the neutral or basic conditions (pH ≥ 7) led to inadequate chromatographic retention for some of the acidic compounds.

Acetaminophen was only poorly ionized in negative ion mode, as the sensitivity was adequate only for monitoring metabolic stability, probably because the acidity of acetaminophen is due to a phenol group that is only a weak acid. The positive ion mode ionization was not very good for acetaminophen in any pH conditions either. For cycloheximide and warfarin, good ionization efficiency in positive ion mode electrospray was observed when 2 mM ammonium formate or 10 mM ammonia was used as aqueous mobile phase even though the imide functionality in the compounds would suggest acidic behavior. Warfarin also showed different behavior in comparison with other acids, as it was very well ionized in both positive and negative ion mode, being therefore easy to analyze by LC--ESI--MS in practically all conditions. The ion chromatograms of warfarin are shown in Figure [2](#F2){ref-type="fig"}. An opposite example of chromatographic performance of acidic compounds is shown in Figure [3](#F3){ref-type="fig"}, where large differences in negative ion mode ionization efficiency for ibuprofen are observed as a function of pH.

![**Positive and negative ion mode LC--ESI--TOF--MS ion chromatograms for warfarin at various mobile phase pH conditions**. **(A)** 0.1% formic acid (pH 2.8); **(B)** 0.1% acetic acid (pH 3.2); **(C)** 2 mM ammonium formate (pH 6.0); **(D)** 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); **(E)** 2 mM ammonium acetate (pH 6.7); **(F)** 10 mM ammonia (pH 9.8). Ionization polarities are shown in each trace.](fphar-01-00010-g002){#F2}

![**Negative ion mode LC--ESI--TOF--MS ion chromatograms for ibuprofen at various mobile phase pH conditions**. **(A)** 0.1% formic acid (pH 2.8); **(B)** 0.1% acetic acid (pH 3.2); **(C)** 2 mM ammonium formate (pH 6.0); **(D)** 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); **(E)** 2 mM ammonium acetate (pH 6.7); **(F)** 10 mM ammonia (pH 9.8).](fphar-01-00010-g003){#F3}

Aminoglutethimide, aminopterin, and nalidixic acid were classified as amphoterics rather than acids, in spite of the presence of acidic imide functionality in aminoglutethimide and carboxylic acid functionality in aminopterin and nalidixic acid. In addition to acidic functionalities, aminoglutethimide contains also basic aniline moiety, whereas aminopterin contains primary amines and aromatic imines, and nalidixic acid contains tertiary amine and aromatic imine functionalities. These basic functionalities also show their effect in observed results, as all of these three compounds were ionized clearly better in positive than in negative ion mode electrospray. With aminopterin also good negative ion mode ionization efficiency was observed in most of the acidic conditions tested. Due to the ionization of the mentioned functionalities, also some chromatographic peak shape and retention problems were observed in acidic and as well as in basic conditions, while the mixture of 0.05% acetic acid and 5 mM ammonium acetate (pH 4.4) showed clearly the best performance with these three compounds. Positive ion mode chromatograms of nalidixic acid are as an example in Figure [4](#F4){ref-type="fig"}, showing very good peak shapes and retention when formic acid, acetic acid or mixture of acetic acid and ammonium acetate are used in mobile phase (traces A, B, and D), but poor peak shape when ammonium formate and ammonium acetate (without acetic acid) are used (traces C and E), and poor peak shape and decreased retention when ammonia is used in mobile phase (trace F).

![**Positive ion mode LC--ESI--TOF--MS ion chromatograms for nalidixic acid at various mobile phase pH conditions**. **(A)** 0.1% formic acid (pH 2.8); **(B)** 0.1% acetic acid (pH 3.2); **(C)** 2 mM ammonium formate (pH 6.0); **(D)** 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); **(E)** 2 mM ammonium acetate (pH 6.7); **(F)** 10 mM ammonia (pH 9.8).](fphar-01-00010-g004){#F4}

Bases
-----

Based on the amine functionalities in the compounds, 25 of them were classified as bases. As expected, a clear majority of them showed ionization efficiency adequate for metabolite profiling in positive ion mode practically in all tested pH conditions. However, when using basic pH conditions or ammonium acetate or ammonium formate in eluents, surprisingly high number of chromatographic peak shape problems were observed. In high pH these are mostly explained by interactions between basic functionalities and free silanol groups remaining in the column, even though the columns used were manufactured with ethylene-bridged silica, resulting in low number of non-end-capped silanols. As with acidic compounds, the generally best chromatographic performance was thus obtained when using low pH eluents, especially with the mixture of 0.05% acetic acid and 5 mM ammonium acetate (pH 4.4). The peak shape problem (good ionization but poor peak shape) is described in Figure [1](#F1){ref-type="fig"} with propranolol, whereas example concerning retention behavior problems is shown in Figure [5](#F5){ref-type="fig"} with nicotine. For nicotine, a satisfactory peak shape but clearly inadequate retention is observed when formic acid, acetic acid, or mixture of acetic acid and ammonium acetate are used in mobile phase (traces A, B, and D). Increased retention but extremely poor peak shape is obtained when using ammonium formate in mobile phase, whereas with ammonium acetate the ionization is suppressed below detection limit. However, when using 10 mM ammonia in mobile phase, an excellent peak shape and good ionization efficiency in positive ion mode are obtained.

![**Positive ion mode LC--ESI--TOF--MS ion chromatograms for nicotine at various mobile phase pH conditions**. **(A)** 0.1% formic acid (pH 2.8); **(B)** 0.1% acetic acid (pH 3.2); **(C)** 2 mM ammonium formate (pH 6.0); **(D)** 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); **(E)** 2 mM ammonium acetate (pH 6.7); **(F)** 10 mM ammonia (pH 9.8). Peaks not integrated are not nicotine-related.](fphar-01-00010-g005){#F5}

In the negative ion mode ionization, a detection sensitivity adequate even for monitoring the parent compound disappearance was rarely obtained for bases, the exception being haloperidol, for which good ionization efficiency was obtained especially with the mixture of 0.05% acetic acid and 5 mM ammonium acetate.

Neutrals
--------

The remaining 17 compounds lacking clearly basic or acidic functional groups, or having no change in calculated logD value over pH range 2--11, were classified as neutrals. Their behavior with respect to ionization efficiency in positive or negative ion mode was generally not so clearly divided, as some showed better ionization in positive and others in negative ion mode. The compounds with better positive ion mode ionization were however in majority over those with more efficient negative ion mode ionization. The slightly acidic 2 mM ammonium formate was observed to be the most suitable of the tested mobile phase conditions for this group of compounds, as the performance with all of the 17 compounds fulfilled the set criteria for monitoring substrate depletion, and with 14 of them the set criteria for metabolite profiling was fulfilled.

Within this class of compounds, problems in chromatography were not observed due to the compounds' poor liquid state ionization properties. Instead, good retention behaviors and excellent peak shapes in all mobile phase pHs were obtained. An example of this is shown in Figure [6](#F6){ref-type="fig"} as ion chromatograms of diuron, where the pH hardly has any effect to chromatography, and only decreasing effect to ionization in negative ion mode with 0.1% formic acid (trace A ESI−) and in positive ion mode with ammonium acetate in mobile phase (trace E ESI+).

![**Positive and negative ion mode LC--ESI--TOF--MS ion chromatograms for diuron at various mobile phase pH conditions**. **(A)** 0.1% formic acid (pH 2.8); **(B)** 0.1% acetic acid (pH 3.2); **(C)** 2 mM ammonium formate (pH 6.0); **(D)** 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); **(E)** 2 mM ammonium acetate (pH 6.7); **(F)** 10 mM ammonia (pH 9.8). Ionization polarities are shown in each trace.](fphar-01-00010-g006){#F6}

Conclusions
===========

Various mobile phase conditions were tested in developing methods for LC--ESI--TOF--MS analysis for metabolite profiling of 55 structurally different compounds. No single or even two different conditions were suitable for covering the whole set of compounds, stressing out that the testing of optimum conditions for each individual compound leads always to clearly more high-quality data. Of the tested conditions, mobile phase with 0.05% acetic acid and 5 mM ammonium acetate provided generally the best performance with easily ionizable compounds (acids and bases), whereas for neutral compounds the best overall performance was obtained with 2 mM ammonium formate as an aqueous mobile phase. The results also suggest that with the used injection solvent conditions, column chemistries, and positive ion mode LC--ESI--MS, poor chromatographic performance, rather than the poor ionization efficiency, may often be the limiting factor in analysis of basic compounds. Noteworthy is also that two very commonly used aqueous mobile phases, i.e. 0.1% formic acid and 2 mM ammonium acetate, showed practically the poorest suitability for LC--ESI--MS analysis for all chemical classes (acids, neutrals, bases) among the different aqueous mobile phases tested.

This in turn suggests that slightly acidic, but not too acidic, pH conditions would be the most optimum for generic LC--ESI--MS analysis of a large set of compounds. However, in this respect recent advances in liquid chromatographic techniques, utilizing sub-2 μm particles and usually referred with names such as ultrahigh performance liquid chromatography (UPLC) (Churchwell et al., [@B6]; Yu et al., [@B19]; Pedraglio et al., [@B16]) or rapid resolution liquid chromatography (Yoshida and Majors, [@B18]), are to some extent improving the problem with poor peak shapes and may lead to a situation where the generic chromatography works increasingly better and more emphasis can be put to ionization conditions. Still, this technical remedy does not however improve the situation with retention behavior but only with peak shapes.

The conditions found here as most suitable for each individual test compound were used in metabolite profiling studies with rat and human liver microsomes and homogenates, providing high-quality data and enabling identification of high number of metabolites for most of the compounds (data will be published elsewhere).
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